In a major development for the biopharmaceutical industry in the Middle East, Omani-based Opal Bio Pharma (OBP) has entered into a strategic partnership with Germany’s pharmaceutical equipment titan, Sartorius. The collaboration was unveiled at the recently concluded CPHI event in Barcelona.
This alliance is set to bolster OBP’s capabilities in producing high-tech biological products, focusing on vital therapeutic areas such as vaccines, oncology, immunology, and gene therapy. Through this partnership, OBP aspires to incorporate cutting-edge European technologies, ensuring that the products are in line with the stringent quality standards of the European Medicines Agency.
The investment for this particular production phase is reported to be upwards of 80 million dollars, highlighting the scale and ambition of the project. Addressing the media, an OBP representative remarked, “With European technology at our disposal, Opal is primed to serve the entire MENA region. This collaboration with Sartorius is a significant stride towards our objective of facilitating timely and cost-effective access to essential medications for the Arab society.”
This partnership signals Opal Bio Pharma’s intent to establish itself as a trailblazer in the biopharmaceutical sector, with an eye on serving the broader MENA region with world-class medicinal solutions. The industry watchers are keenly observing the potential innovations and breakthroughs this collaboration might usher in.
